SCHEMBL30712094

SCHEMBL30712094

CCNC(=O)C(=O)c1c[nH]c2c(Br)cc(F)c(OCc3ccccc3)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ THRA P10827 2/20 0.38
▸ THRB P10828 2/20 0.38
▸ GABRP O00591 4/20 0.37
▸ GABRD O14764 4/20 0.37
▸ GABRA1 P14867 4/20 0.37
▸ GABRB1 P18505 4/20 0.37
▸ GABRG2 P18507 4/20 0.37
▸ GABRB3 P28472 4/20 0.37
▸ GABRA5 P31644 4/20 0.37
▸ GABRA3 P34903 4/20 0.37
▸ GABRA2 P47869 4/20 0.37
▸ GABRB2 P47870 4/20 0.37
▸ GABRA4 P48169 4/20 0.37
▸ GABRE P78334 4/20 0.37
▸ GABRA6 Q16445 4/20 0.37
▸ GABRG1 Q8N1C3 4/20 0.37
▸ GABRG3 Q99928 4/20 0.37
▸ GABRQ Q9UN88 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30712065 0.92 KMT2A (0.39) BRD4SMN1; SMN2THRATHRBGABRP
SCHEMBL31708089 0.90 SMN1; SMN2 (0.42) BRD4SMN1; SMN2THRATHRBNPC1
SCHEMBL31708198 0.87 THRA (0.37) SMN1; SMN2THRATHRBNPC1LMNA
SCHEMBL1163916 0.87 LMNA (0.40) SMN1; SMN2THRATHRBNPC1HTT
SCHEMBL31708099 0.86 THRA (0.42) SMN1; SMN2THRATHRBNPC1HTT
SCHEMBL31708095 0.85 THRA (0.44) SMN1; SMN2THRATHRBNPC1HPGD
SCHEMBL30712089 0.77 DPP4 (0.36) THRATHRBNPC1
SCHEMBL1163307 0.76 THRB (0.45) SMN1; SMN2THRATHRBNPC1KMT2A
SCHEMBL4391284 0.74 LTB4R (0.37) BRD4SMN1; SMN2NPC1KMT2AJAK2
SCHEMBL31708137 0.74 MTNR1A (0.36) SMN1; SMN2GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635492-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-10-22 — — EP disclosed
EP-4551212-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS Gilgamesh Pharmaceuticals, Inc. (US) 2025-05-14 — — EP disclosed
WO-2024035757-A2 TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2024-02-15 — — WO disclosed
Send feedback